Innovation Pharmaceuticals Inc (IPIX)

[eddiebali]

In your opinion do you think that this statement means Kevetrin is being tested with several different combinations???

and with the sunitnib combination a first tumor shrinkage was noted.

Or does it mean first time they noted shrinkage in a renal cancer tumor?

" Research by BIDMC combined Kevetrin™ with sunitinib on cell line 786, a drug-resistant renal cancer. Cellceutix was advised by the researchers that "the Kevetrin/sunitinib combination is the first we've used in which actual tumor shrinkage is noted."



2007: Sunitinib ; The first Phase III study comparing an RTKI with cytokine therapy was published in the New England Journal of Medicine . This study showed that Sunitinib offered superior efficacy compared with interferon-? . Progression-free survival (the primary endpoint) was more than doubled. The benefit for sunitinib was significant across all major patient subgroups, including those with a poor prognosis at baseline. 28% of sunitinib patients had significant tumor shrinkage compared with only 5% of patients who received interferon-?. Although overall survival data are As of 2007 not yet mature, there is a clear trend toward improved survival with sunitinib. Patients receiving sunitinib also reported a significantly better quality of life than those treated with IFNa. [48]

http://en.wikipedia.org/wiki/Renal_cell_carcinoma